-FirstPost.com Uncertainty over the supply of subsidised foodgrain to over 19 lakh families in Assam whose livelihoods are linked to work in the tea gardens is threatening to not only spark dissent among workers but has got the industry leaders worried. To understand the impact, consider the case of Deepak Daori and Monica Daori - both workers at Mokalbari Tea Estate in Dibrugarh district. "We are worried that the our monthly ration might...

-Business Standard This would be in addition to 348 drugs already under price ceiling The National Pharmaceutical Pricing Authority (NPPA) has capped the prices of another 52 essential drugs, in a move that could impact drug manufacturers Lupin, Cadila Healthcare and Merck. This is in addition to the 348 drugs already under a price ceiling. The majority of the 52 new drugs are antibiotics, painkillers and medicines used for treating cancer and skin...

-Business Standard Domestic regulators need to be stricter about quality violations to protect both Indian pharma exports as well as the country's image Even as major Indian drug companies continue to make news for impurities in the medicines they make and faulty - or if the USFDA is to be believed, falsified - data that many generate after testing of samples show quality problem, it seems strange that domestic authorities are silent...

-The Indian Express Three members of a Dalit family in Maharashtra's Ahmednagar were killed, one of them decapitated before being thrown into a dry well in Jawkhede Khalsa village, on the night of October 20. The investigation is still on and the jury out on whether it was an act of caste violence or the result of a dispute. In recent times, however, it seems there is a surge in the...

-The Times of India MUMBAI: Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law. Corporates such as Japanese firm Otsuka Pharmaceuticals, US-based Bristol Myers-Squibb (BMS) and Swiss firm Novartis are deferring the launch of medicines critical for treatment of serious non-communicable diseases like cancer, HIV,...